Also found in: Medical.
CINVChemotherapy Induced Nausea and Vomiting
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
'Our CINV franchise continues to perform well, highlighted by strong net product sales in the second quarter.'
The company added that the CINVANTI (aprepitant) injectable emulsion for intravenous (IV) use is the first and only polysorbate 80-free, IV formulation of an NK1 receptor antagonist (RA) indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).
One study carried out on Indonesians has shown that this genetic variant of 5-HT3B gene and the clinical response were not associated to each other.11 Recently a study conducted on Chinese Han population could also not find any significant association between 18792A>G polymorphism and the incidence of CINV in patients of acute myeloid leukaemia.10 We too couldn't observe any significant impact of HTR3B variant on the anti-emetic response in our post-operative patients.
This is an important moment for Helsinn, as it allows us to bring an additional option to patients experiencing CINV in highly emetogenic chemotherapy treatment."
There is good evidence of effectiveness in managing chronic and neuropathic pain, spasticity, CINV, anxiety, and epilepsy in children.
Nabilone, a potent agonist of the [CB.sub.1] receptor, became available as a Schedule II medication in 1981 and was approved for patients with chemotherapy-induced nausea and vomiting (CINV).
Previous studies have reviewed the used of ginger supplementation in preventing CINV; however, results have been inconclusive and standardised compounds were not used.
The NDA filing includes data demonstrating the bioequivalence of CINVANTI to EMEND IV (fosaprepitant), supporting its efficacy for the prevention of both acute and delayed CINV with both moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC).
Considering the duration of nausea and vomiting, CINV can be classified into the following categories: acute CINV, which occurs in a few minutes of chemotherapy and can be relieved in 24 hours; delayed CINV, which occurs after more than 24 hours, typically reaches its peak from 48 to 72 hours, and can last 5 days after chemotherapy; and anticipatory emesis, which may occur when patients see or smell the chemotherapeutic drugs [1, 6].
Aprepitant was first approved in the United States in March 2003 to prevent chemotherapy-induced nausea and vomiting (CINV) [1].
Chemotherapy-induced Nausea and Vomiting (CINV) can be defined as acute CINV, delayed CINV or anticipatory CINV.
This work was supported by FONDECYT (1120513), the Millennium Institute CINV (ICM P99-037-F), the Kerstan Foundation, the Deutsche Forschungsgemeinschaft (DFG PA 1751/71), the Alcon Research Institute, the European Commission [DRUGSFORD: HEALTH-F2-2012-304963], and Fundacion Gangoiti Barrera.